Rivaroxaban CAS 366789-02-8 Puritas >99.5% (HPLC) Factory API Quality
Manufacturer Supple Rivaroxaban intermedia:
(S)-(+)-Glycidyl Phthalimide CAS 161596-47-0
4-(4-Aminophenyl) morpholin-3-one CAS 438056-69-0
Rivaroxaban Intermediate CAS 446292-07-5
5-Chlorothiophene-2-Carboxylic Acidum CAS 24065-33-6
5-Chlorothiophene-2-Carbonyl Chloride CAS 42518-98-9
Rivaroxaban API CAS 366789-02-8
Nomen chemicum | Rivaroxaban |
Synonyma | (S) -Rivaroxaban;(S) -5-Chloro-N-((2-oxo-3-(4-(3-oxomorpholino)phenyl)-oxazolidin-5-yl)methyl)thiophene-2-carbox;BAV 59-7939 |
CAS Number | 366789-02-8 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C19H18ClN3O5S |
M. Pondus | 435.88 |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Alba aut fere Alba pulveris |
Lepidium sativum | Infrared effusio Rivaroxaban respondet signis referentibus |
Lepidium sativum B * | Retentionis tempus praecipui solutionis specimen summae correspondet solutioni convenientiae systematis, prout in puritate enantiomericana obtinetur. |
Puritas Enantiomeric | RVX RC01: ≤0.15% |
Humor (KF) | ≤0.50% |
Cinis sulphated | ≤0.10% |
Metalla gravis | ≤20ppm |
Acidum acetic | ≤5000ppm |
Substantiae cognatae (HPLC) | |
RVX RC02 | ≤0.15% |
RVX RC03 | ≤0.15% |
RVX RC04 | ≤0.15% |
RVX RC05 | ≤0.15% |
RVX RC06 | ≤0.15% |
RVX RC07 | ≤0.15% |
RVX RC08 | ≤0.15% |
Alia individua immunditia | ≤0.10% |
Totalis immunditias | <0.50% |
RELICTUM Solvents (GC) | |
Ethanol | ≤5000ppm |
Toluene | ≤890ppm |
Triethylamine | ≤320ppm |
Puritas / Analysis Methodus | >99.5% (HPLC) (on anhydrous basis) |
Test Standard | Enterprise Standard |
Consuetudinem | API;Antithrombotic medicamentum;FXa Inhibitor |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.
Rivaroxaban(CAS:366789-02-8) (Xarelto, Bayer) oralis anticoagulans est.Xa factor inhibitor oretenus directus est activus.Rivaroxaban significatur per "tractationem venae profundae thrombosis et embolismi pulmonis, et praeventionis recurrentis venae altae thrombosis et embolismi pulmonis in adultis".Ad tractationem initialem embolismi pulmonis acuti, dosis rivaroxabani commendatus est 15 mg bis cotidie pro primis 21 diebus, deinde 20 mg semel cotidie ad curatio continua et praeventionis thromboembolismi venarum recurrentis.Fibrillatio non-valvular atrialis (NVAF) ad praecavendam ictum & embolismum systemicum.Curatio acuta VTE & praeventionis VTE recurrentis [pro venae profundae thrombosis (DVT) et embolismi pulmonis (PE)].Praeventio venarum thromboembolicarum eventus (VTE) in totali coxae vel genu chirurgiae electivae (THR, TKR).